Synthesis methodology, HPLC + MS verification, lot traceability, and the published research behind the compounds in our catalog.
77 studies is a lot to read cold. Answer four questions and we will point you at the ones that match what you are actually tracking.
Phase 3 randomized, double-blind, placebo-controlled trial (STEP 1) of once-weekly semaglutide 2.4 mg vs placebo in 1961 adults with overweight/obesity without diabetes; 68 weeks. Primary endpoint: percent change in body weight.
Phase 3 randomized, double-blind, double-dummy, placebo-controlled trial of subcutaneous semaglutide 2.4 mg vs 1.0 mg vs placebo over 68 weeks in adults with overweight/obesity and type 2 diabetes. Primary endpoint: change in body weight and HbA1c.
Randomized clinical trial in 611 adults comparing 68 weeks of once-weekly subcutaneous semaglutide vs placebo, both combined with intensive behavioral therapy and an initial low-calorie diet. Primary endpoint: percent change in body weight.
Phase 3 randomized, double-blind, placebo-controlled trial (SURMOUNT-1) of once-weekly tirzepatide 5/10/15 mg vs placebo over 72 weeks in 2539 adults with obesity without diabetes. Primary endpoint: percent change in body weight.
40-week phase 3 open-label randomized trial (SURPASS-2) in 1879 adults with type 2 diabetes comparing tirzepatide 5/10/15 mg vs semaglutide 1 mg, both subcutaneous once weekly. Primary endpoint: change in HbA1c from baseline.
Phase 2 randomized, double-blind, placebo-controlled trial of subcutaneous retatrutide (GIP/GLP-1/glucagon agonist) at 1, 4, 8, 12 mg vs placebo over 48 weeks in 338 adults with obesity. Primary endpoint: percent change in body weight.
Multinational double-blind randomized trial (LEADER) in 9340 adults with type 2 diabetes and high cardiovascular risk; once-daily subcutaneous liraglutide 1.8 mg vs placebo, median 3.8 years. Primary endpoint: composite cardiovascular death, nonfatal MI, nonfatal stroke.
56-week double-blind randomized trial (SCALE) in 3731 adults without type 2 diabetes; once-daily subcutaneous liraglutide 3.0 mg vs placebo, both with lifestyle counseling. Primary endpoint: change in body weight.
Phase 3 double-blind randomized trial (SUSTAIN-6) in 3297 adults with type 2 diabetes and high cardiovascular risk; once-weekly subcutaneous semaglutide 0.5 or 1.0 mg vs placebo, 104 weeks. Primary endpoint: composite cardiovascular death, nonfatal MI, nonfatal stroke.
Phase 2 randomized, double-blind, placebo-controlled trial of once-weekly mazdutide (GLP-1/glucagon dual agonist) at 3, 4.5, 6 mg vs placebo over 24 weeks in 248 Chinese adults with overweight/obesity. Primary endpoint: percent change in body weight.
Phase 2 dose-finding randomized, double-blind, placebo-controlled trial of once-weekly subcutaneous survodutide (GLP-1/glucagon dual agonist) at 0.6 to 4.8 mg vs placebo, 46 weeks, in 387 adults with obesity. Primary endpoint: percent change in body weight.
Randomized, controlled phase 1b trial characterizing safety, PK and PD of concomitant subcutaneous cagrilintide (amylin analogue) escalated 0.16 to 4.5 mg with semaglutide 2.4 mg once weekly over 20 weeks. Endpoints: tolerability, exposure, body-weight change.
Prospective placebo-controlled veterinary clinical trial in 30 client-owned newly diagnosed diabetic cats receiving once-weekly subcutaneous exenatide ER vs saline, all on insulin glargine and low-carb diet. Endpoints: safety, body weight, remission, metabolic control.
Veterinary study evaluating combined GLP-1 mimetic and insulin glargine in client-owned diabetic cats. Endpoints: glycemic control, insulin requirement, adverse events across treatment period.
Rat model of Achilles tendon-to-bone detachment characterizing intraperitoneal BPC 157 vs corticosteroid co-administration. Endpoints: histology, biomechanical load-to-failure, functional index over the postoperative window.
Preclinical rat study of fully transected Achilles tendon characterizing BPC 157 effects on functional, histologic, and biomechanical healing kinetics, with paired in vitro tendocyte proliferation assay.
In vitro mechanistic study characterizing BPC 157 on tendon explant outgrowth, tendon fibroblast survival under stress, and migration via FAK-paxillin pathway. Endpoints: outgrowth area, viability, dose-response migration.
Rat model of surgically transected medial collateral ligament characterizing BPC 157 by intraperitoneal, oral, and topical routes over 90 days. Endpoints: valgus instability, load-to-failure, collagen organization at 14/30/45/90 days.
Narrative review of preclinical BPC 157 across rodent gut, tendon, ligament, muscle and bone injury models, mapping VEGFR2/NO pathway engagement and angiogenic mechanism. Endpoint: synthesized model-by-model evidence.
Rat gastrocnemius muscle crush-injury model characterizing BPC 157 by intraperitoneal and intragastric routes. Endpoints: macro/microscopic healing, functional walking recovery, longitudinal time course.
Preclinical full-thickness dermal wound study in db/db diabetic and aged mice characterizing thymosin beta 4 and a synthetic actin-binding domain peptide. Endpoints: keratinocyte migration, wound contracture, collagen deposition.
In vivo mouse model of corneal alkali injury characterizing topical thymosin beta 4 vs vehicle. Endpoints: re-epithelialization rate, polymorphonuclear leukocyte infiltration, inflammatory cytokine mRNA.
Rat full-thickness dermal wound model characterizing systemic and topical thymosin beta 4. Endpoints: wound area closure rate, re-epithelialization, collagen deposition over the healing window.
db/db diabetic mouse burn wound model characterizing thymosin beta 4 effects with mechanistic readout of RAGE expression. Endpoints: histologic healing, RAGE/inflammation markers across the healing time course.
Pharmacology characterization of ipamorelin in primary rat pituitary cells and in vivo, with comparison to GHRP-6. Endpoints: GH potency/efficacy, ACTH/cortisol selectivity profile via receptor antagonist studies.
Rat in vivo study of chronic ipamorelin administration characterizing longitudinal bone growth and body-weight gain vs GHRP-6 and GH. Endpoints: tibial growth plate width, body weight trajectory.
Two randomized, double-blind, placebo-controlled, ascending-dose trials (28 and 49 days) in healthy adults aged 21-61. Endpoints: plasma GH and IGF-I time-course, half-life estimation, tolerability.
Healthy-adult pharmacodynamic study characterizing pulsatile GH secretion under sustained CJC-1295 stimulation via frequent sampling. Endpoints: GH pulse frequency/amplitude, IGF-I trajectory.
12-month clinical study of continuous subcutaneous GHRH(1-29)NH2 (sermorelin) in short, slowly growing children. Endpoints: height velocity, IGF-I response.
Pharmacologic review of sermorelin (GHRH 1-29) covering diagnostic provocative testing and pediatric idiopathic GH deficiency literature. Synthesizes clinical pharmacokinetics and growth response endpoints.
Phase 3 randomized, double-blind, placebo-controlled trial in 412 HIV-infected adults with abdominal fat accumulation; 26 weeks of daily subcutaneous tesamorelin 2 mg vs placebo. Primary endpoint: change in visceral adipose tissue by CT.
Phase 3 randomized placebo-controlled trial with safety extension in HIV-infected adults with central fat accumulation. Endpoints: visceral adipose tissue, lipid profile, glucose parameters across the extension window.
Acute pharmacodynamic study of hexarelin in hypopituitary adults vs healthy controls characterizing cardiac response. Endpoints: left ventricular ejection fraction by echocardiography, GH response.
In vitro study of MGF-E peptide (IGF-1 splice variant) in human muscle progenitor cells from neonatal, young adult and old donors. Endpoints: proliferative lifespan, senescence markers, myotube fusion index.
Mechanistic review of MGF (IGF-1Ec) splicing biology, satellite cell activation pathways, and the literature on MGF in skeletal muscle, cartilage and bone repair models. Synthesizes signaling and regeneration endpoints.
Mechanistic study in intestinal epithelial cells and DSS- and TNBS-induced murine colitis models characterizing PepT1-mediated KPV uptake and NF-kappaB modulation. Endpoints: MPO activity, histology, cytokine mRNA.
Murine DSS colitis model characterizing orally administered KPV-loaded hyaluronic acid nanoparticles. Endpoints: colonic targeting, inflammation markers, histologic damage scoring.
Discovery study identifying the 16-aa mitochondrial-derived peptide MOTS-c. Characterized in skeletal muscle and in mice on high-fat diet. Endpoints: AMPK activation, insulin sensitivity, body composition.
Mouse and human plasma study characterizing MOTS-c as a regulator of metabolites and insulin sensitivity. Endpoints: metabolomic profile, glucose disposal, exercise-associated MOTS-c levels.
Mechanistic review of GHK-Cu integrating gene-expression datasets (CMap), preclinical wound and skin studies, and copper-binding biochemistry. Synthesizes pathway-level endpoints across regenerative models.
Review characterizing GHK plasma decline with chronological age and consolidating in vitro/animal data on collagen, elastin, and gene-expression endpoints relevant to skin and connective tissue.
In vitro keratinocyte/endothelial assays paired with in vivo rat wound model characterizing LL-37. Endpoints: vascularization, re-epithelialization rate, cell migration over the healing window.
Meta-analysis of nine randomized controlled trials (n=1879) of cerebrolysin in acute ischemic stroke. Endpoints: NIHSS at day 30, mortality, adverse-event rates.
Multicenter double-blind randomized placebo-controlled trial (CASTA) of intravenous cerebrolysin within 12 h of acute ischemic stroke in Asia. Endpoints: composite NIHSS, mRS, Barthel at day 90.
Clinical comparison study (n=62) of intranasal selank vs medazepam in generalized anxiety disorder and neurasthenia. Endpoints: Hamilton anxiety scale, Zung, CGI; plasma leu-enkephalin.
Open clinical study evaluating intranasal semax across acute and recovery phases of ischemic stroke. Endpoints: NIHSS motor performance, Barthel index, plasma BDNF.
Rat focal photoinduced prefrontal-cortex ischemia model characterizing intranasal semax. Endpoints: cortical infarct volume, conditioned passive-avoidance retention.
Mechanistic in vitro and rat in vivo study characterizing dihexa and Nle1-AngIV effects via HGF/c-Met. Endpoints: c-Met phosphorylation, hippocampal spinogenesis, Morris water-maze performance.
Review consolidating angiotensin IV analog development including dihexa, BBB permeability, and HGF/c-Met-mediated synaptogenesis findings across rodent learning and memory paradigms.
Review characterizing the aged-beagle canine model of cognitive aging and its pharmacologic validity for evaluating neuroactive compounds. Synthesizes neuropathology and behavioral testing endpoints.
Veterinary characterization of canine cognitive dysfunction as a translational dementia model, with cognitive testing battery and response to 1-deprenyl. Endpoints: clinical signs, neuropathology, behavioral scores.
Lifelong subcutaneous administration of tetrapeptide epitalon (Ala-Glu-Asp-Gly) in female outbred SHR mice. Endpoints: body weight, mean and maximum lifespan, spontaneous tumor incidence including leukemia.
Comparison of epitalon and melatonin in senescence-accelerated SAMP-1 and SAMR-1 mice. Endpoints: mean and maximum survival in last-decile survivors, tumor incidence and time-to-detection.
Review of short peptide bioregulators (epitalon, thymalin, vilon, others), summarizing rodent lifespan, telomere, immune and endocrine endpoints across decades of experimental work.
Review consolidating mechanism studies of short peptides on gene expression, proliferation, apoptosis, and the long-term clinical follow-up of peptide bioregulators in elderly cohorts.
In vitro study in normal and ALT-positive human cell lines characterizing epitalon effects on telomere length and telomerase. Endpoints: qPCR telomere length, hTERT expression, immunofluorescence.
Discovery and characterization of mitochondrial-derived peptide MOTS-c in skeletal muscle and aged mice fed high-fat diet. Endpoints: AMPK activation, age-dependent insulin resistance, body composition.
Long-term observational follow-up over 15 years of elderly cohorts receiving thymic and pineal peptide bioregulators. Endpoints: all-cause mortality, age-related morbidity profile.
Preclinical nonhuman primate trial of long-term intermittent dasatinib + quercetin senolytic regimen. Endpoints: senescence markers, systemic inflammation, functional aging outcomes over the dosing window.
Two identical phase 3 randomized, double-blind, placebo-controlled trials (RECONNECT) in 1267 premenopausal women with HSDD; subcutaneous bremelanotide 1.75 mg as-needed vs placebo over 24 weeks. Primary endpoints: FSFI desire and FSDS-DAO item 13.
52-week open-label extension of the RECONNECT trials characterizing long-term safety and durability of subcutaneous bremelanotide as-needed in premenopausal women with HSDD. Endpoints: adverse events, sustained FSFI/FSDS scores.
Double-blind placebo-controlled study of intranasal PT-141 in healthy men and men with mild-to-moderate erectile dysfunction. Endpoints: safety, plasma PK, RigiScan-measured erectile response.
Phase 1 study characterizing subcutaneous PT-141 safety, PK and pharmacodynamics in healthy men and men with inadequate sildenafil response. Endpoints: tolerability, plasma exposure, RigiScan-measured response.
Randomized double-blind placebo-controlled fMRI crossover study of intravenous kisspeptin-54 in healthy men viewing sexual and emotional stimuli. Endpoints: BOLD activity in limbic and reward regions, mood scales.
Randomized double-blind placebo-controlled crossover trial of intravenous kisspeptin-54 in 32 premenopausal women with HSDD. Endpoints: task-based fMRI BOLD responses to sexual stimuli, sexual response scales.
Randomized double-blind placebo-controlled fMRI crossover study of intravenous kisspeptin-54 in men with HSDD. Endpoints: BOLD response in sexual-processing network, penile tumescence, mood scales.
Pilot clinical study of intracavernous VIP combined with phentolamine mesylate in men with erectile dysfunction. Endpoints: erectile response, partner-reported satisfaction, adverse events.
Randomized double-blind placebo-controlled crossover study of intranasal oxytocin adjunctive to antipsychotics in schizophrenia. Endpoints: PANSS total, social-cognition measures across the dosing period.
Multicenter single-blind randomized controlled trial (ETASS) of subcutaneous thymosin alpha 1 vs control in adults with severe sepsis across six tertiary ICUs in China. Primary endpoint: 28-day all-cause mortality.
Multicenter double-blind placebo-controlled phase 3 trial (TESTS) of subcutaneous thymosin alpha-1 in 1106 adults with sepsis. Primary endpoint: 28-day all-cause mortality; secondary: organ-failure-free days.
Randomized controlled trial of subcutaneous thymosin alpha 1 in 98 adults with chronic hepatitis B over 26 vs 52 weeks vs untreated controls. Endpoints: HBV DNA clearance, HBeAg seroconversion at 18 months.
Randomized clinical trial in 316 Japanese adults with chronic hepatitis B comparing subcutaneous thymosin alpha 1 0.8 vs 1.6 mg twice weekly for 24 weeks. Endpoints: ALT normalization, HBV-DNA and HBeAg clearance at 72 weeks.
Double-blind randomized controlled trial of subcutaneous thymosin alpha 1 in adults with severe acute pancreatitis. Endpoints: T-lymphocyte subsets, infection incidence, length of stay.
In vitro characterization of LL-37 against gram-positive and gram-negative pathogens and biofilms relevant to polymicrobial wound infection. Endpoints: MIC, anti-biofilm activity, host-cell viability.
Mechanistic review of LL-37 as a multitask host-defense peptide spanning antimicrobial activity, LPS neutralization, chemotaxis, and re-epithelialization across in vitro and animal models.
Human acute vs chronic skin-wound study characterizing LL-37 expression in re-epithelializing epidermis. Endpoints: immunohistochemistry, in vitro keratinocyte migration with LL-37 blockade.
Randomized controlled trial of subcutaneous thymosin alpha-1 added to standard care in adults with HBV-related acute-on-chronic liver failure. Endpoints: 90-day transplant-free survival, infection rate.